Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience

Archives of Virology

Volumn 160, Issue 11, 2015, Pages 2881-2885

  Ruggiero, Tina ^a   Proietti, Alex ^a   Boglione, Lucio ^b   Milia, Maria Grazia ^a   Allice, Tiziano ^a   Burdino, Elisa ^a   Orofino, Giancarlo ^a   Bonora, Stefano ^b   Di Perri, Giovanni ^b   Ghisetti, Valeria ^a  

^a AMEDEO DI SAVOIA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; SIMEPREVIR; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; CLASSIFICATION; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MOLECULAR GENETICS; VIROLOGY;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; SIMEPREVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84946490901     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-015-2563-3     Document Type: Article

References (33)

1. Liang TJ, Ghany MG (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 368:1907–1917. doi:10.1056/NEJMra1213651
2. Schneider MD, Sarrazin C (2014) Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res 105:64–71. doi:10.1016/j.antiviral.2014.02.011
3. De Luca A, Bianco C, Rossetti B (2014) Treatment of HCV infection with the novel NS3/4A protease inhibitors. Curr Opin Pharmacol 18C:9–17. doi:10.1016/j.coph.2014.07.016
4. Schweitzer CJ, Liang TJ (2013) Impact of host and virus genome variability on HCV replication and response to interferon. Curr Opin Virol 3:501–507. doi:10.1016/j.coviro.2013.06.005
5. Bartels DJ, Zhou Y, Zhang EZ et al (2008) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198:800–807. doi:10.1086/591141
6. Vicenti I, Rosi A, Saladini F et al (2012) Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 67:984–987. doi:10.1093/jac/dkr581
7. Sarrazin C, Kieffer TL, Bartels D et al (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767–1777. doi:10.1053/j.gastro.2007.02.037
8. Susser S, Welsch C, Wang Y et al (2009) Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709–1718. doi:10.1002/hep.23192
9. Boglione L, De Nicolò A, Cardellino CS et al (2015) Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. Clin Microbiol Infect 21(205):e1–e3. doi:10.1016/j.cmi.2014.07.009
10. Palanisamy N, Danielsson A, Kokkula C et al (2013) Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 99:12–17. doi:10.1016/j.antiviral.2013.04.018
11. Jacobson IM, Dore GJ, Foster GR et al (2014) Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384:403–413. doi:10.1016/S0140-6736(14)60494-3
12. Manns M, Marcellin P, Poordad F et al (2014) Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384:414–426. doi:10.1016/S0140-6736(14)60538-9
13. Lenz O, Verbinnen T, Lin TI et al (2010) In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54:1878–1887. doi:10.1128/AAC.01452-09
14. Vallet S, Viron F, Henquell C et al (2011) NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antiviral Ther 16:1093–1102. doi:10.3851/IMP1900
15. Shepherd SJ, Abdelrahman T, MacLean AR et al (2015) Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 65:50–53. doi:10.1016/j.jcv.2015.02.005
16. Nguyen LT, Gray E, Dean J, Carr M, Connell J, De Gascun C, Nguyen LA, O’Leary A, Bergin C, Hall WNS (2015) Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals. Antiviral Ther 107:3851. doi:10.3851/IMP2964
17. Manns MP, Fried MW, Zeuzem S et al (2014) Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. J Viral Hepat 22:366–375. doi:10.1111/jvh.12346
18. Bae A, Sun SC, Qi X et al (2010) Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 54:5288–5297. doi:10.1128/AAC.00777-10
19. Pickett BE, Striker R, Lefkowitz EJ (2011) Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 18:608–618. doi:10.1111/j.1365-2893.2010.01342.x
20. Sarrazin C, Lathouwers E, Peeters M et al (2015) Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 116:10–16. doi:10.1016/j.antiviral.2015.01.003
21. Lawitz E, Sulkowski MS, Ghalib R et al (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384:1756–1765. doi:10.1016/S0140-6736(14)61036-9
22. EASL (European Association for Study of Liver) (2014) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60:392–420. doi:10.1016/j.jhep.2013.11.003
23. Janssen (2013) Olysio (Simeprevir). Highlights of prescribing information. Janssen Product, LP, Titusville
24. Berger KL, Triki I, Cartier M et al (2014) Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Antimicrob Agents Chemother 58:698–705. doi:10.1128/AAC.01976-13
25. HCV, DRM (HCV Phenotype Working Group). HCV Drug Development Advisory Group (2012) Clinically relevant HCV Drug resistance mutations figure and tables. Public Health 14:1–8
26. Morsica G, Bagaglio S, Uberti-Foppa C, LA Galli L (2009) Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV-HCV coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 51(106–10):104–110
27. Ogishi M, Yotsuyanagi H, Tsutsumi T et al (2015) Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. PLoS ONE 10:e0119145. doi:10.1371/journal.pone.0119145
28. Silva T, Cortes Martins H, Coutinho R, Leitao E, Silva RPE (2015) Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV. J Med Virol. doi:10.1002/jmv.24213
29. Ehret R, Neifer S, Walter H et al (2014) Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory. J Int AIDS Soc 17:19741
30. Halfon P, Bourliere MKH et al (2008) Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy. AIDS 22(1683–1):1683–1698
31. Trimoulet P, Belzunce C, Faure M et al (2011) Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Med 12:506–509. doi:10.1111/j.1468-1293.2011.00913.x
32. Kieffer TL, George S (2014) Resistance to hepatitis C virus protease inhibitors. Curr Opin Virol 8:16–21
33. Lenz O, Fevery K, Thys K et al (2013) Simeprevir in HCV genotype-1-infected patients: deep sequencing analyses of the PILLAR and ASPIRE Phase IIb trials. Antiviral Ther 18 suppl 1A:14